The Manufacturers Life Insurance Company raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,541 shares of the biopharmaceutical company’s stock after purchasing an additional 167 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Alnylam Pharmaceuticals were worth $203,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of ALNY. QS Investors LLC increased its stake in Alnylam Pharmaceuticals by 59.7% in the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares in the last quarter. CIBC Asset Management Inc bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at $221,000. Neuberger Berman Group LLC bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at $229,000. Capstone Asset Management Co. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $232,000. Finally, Quantbot Technologies LP grew its holdings in shares of Alnylam Pharmaceuticals by 250.3% during the second quarter. Quantbot Technologies LP now owns 3,139 shares of the biopharmaceutical company’s stock valued at $250,000 after buying an additional 2,243 shares during the last quarter. 88.43% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at $130.89 on Monday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $35.98 and a twelve month high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. During the same quarter last year, the firm posted ($1.21) earnings per share. The firm’s revenue for the quarter was up 24.8% compared to the same quarter last year. equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current year.

A number of research analysts have recently issued reports on ALNY shares. Needham & Company LLC reiterated a “buy” rating and set a $85.00 price objective (down from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. BMO Capital Markets reiterated an “outperform” rating and set a $99.00 price objective (down from $105.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 6th. Instinet started coverage on shares of Alnylam Pharmaceuticals in a report on Friday, September 15th. They set a “reduce” rating and a $56.00 price objective for the company. Piper Jaffray Companies reiterated an “overweight” rating and set a $110.00 price objective (down from $126.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Finally, Leerink Swann reiterated a “market perform” rating and set a $72.00 price objective (down from $83.00) on shares of Alnylam Pharmaceuticals in a report on Friday, September 8th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $121.85.

In related news, SVP Laurie Keating sold 30,000 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the transaction, the senior vice president now directly owns 41,500 shares in the company, valued at $5,639,435. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO John Maraganore sold 74,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the transaction, the chief executive officer now owns 223,710 shares in the company, valued at $28,379,850.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 393,212 shares of company stock worth $48,109,436. 4.30% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/11/alnylam-pharmaceuticals-inc-alny-shares-bought-by-the-manufacturers-life-insurance-company.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.